Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLCG1 | P19174 | 14/20 | 0.77 |
| ▸ | BTK | Q06187 | 6/20 | 0.67 |
| ▸ | ITK | Q08881 | 6/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17939521 | 0.90 | PLCG1 (0.65) | PLCG1BTKITK | |
| SCHEMBL17938946 | 0.89 | PLCG1 (0.85) | PLCG1BTKITK | |
| SCHEMBL17939446 | 0.88 | PLCG1 (0.63) | PLCG1BTKITK | |
| SCHEMBL17939447 | 0.88 | PLCG1 (0.63) | PLCG1BTKITK | |
| SCHEMBL17938947 | 0.87 | PLCG1 (0.82) | PLCG1BTKITK | |
| SCHEMBL17939428 | 0.87 | PLCG1 (1.00) | PLCG1BTKITK | |
| SCHEMBL17938959 | 0.86 | PLCG1 (0.76) | PLCG1BTKITK | |
| SCHEMBL17939787 | 0.86 | PLCG1 (0.62) | PLCG1BTKITK | |
| SCHEMBL17939788 | 0.86 | PLCG1 (0.62) | PLCG1BTKITK | |
| SCHEMBL17939223 | 0.86 | PLCG1 (1.00) | PLCG1BTKITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190106439-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | CONFLUENCE LIFE SCIENCES, INC. | 2019-04-11 | — | — | US | claimed |
| US-10150783-B2 | Heterocyclic ITK inhibitors for treating inflammation and cancer | ACLARIS THERAPEUTICS, INC. (US) | 2018-12-11 | — | — | US | claimed |
| US-20170260211-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2017-09-14 | — | — | US | claimed |
| US-20160213653-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2016-07-28 | — | — | US | claimed |
| US-20190106439-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | CONFLUENCE LIFE SCIENCES, INC. | 2019-04-11 | — | — | US | disclosed |
| US-20190106439-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | CONFLUENCE LIFE SCIENCES, INC. | 2019-04-11 | — | — | US | disclosed |
| US-10150783-B2 | Heterocyclic ITK inhibitors for treating inflammation and cancer | ACLARIS THERAPEUTICS, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20170260211-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170260211-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170260211-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9695200-B2 | Heterocyclic ITK inhibitors for treating inflammation and cancer | CONFLUENCE LIFE SCIENCES, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695200-B2 | Heterocyclic ITK inhibitors for treating inflammation and cancer | CONFLUENCE LIFE SCIENCES, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-9695200-B2 | Heterocyclic ITK inhibitors for treating inflammation and cancer | CONFLUENCE LIFE SCIENCES, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160213653-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160213653-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
| WO-2016118951-A2 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | CONFLUENCE LIFE SCIENCES, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20160213653-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ACLARIS THERAPEUTICS, INC. | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106439-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, NFKBIA, TNNI3K | PLCG1 3621/4885BTK 481/4885ITK 1/4885 |
| US-20170260211-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, NFKBIA, TNNI3K | PLCG1 3621/4885BTK 481/4885ITK 1/4885 |
| US-20160213653-A1 | HETEROCYCLIC ITK INHIBITORS FOR TREATING INFLAMMATION AND CANCER | ITK, NFKBIA, TNNI3K | PLCG1 3621/4885BTK 481/4885ITK 1/4885 |
| US-10150783-B2 | Heterocyclic ITK inhibitors for treating inflammation and cancer | ITK, NFKBIA, TNNI3K | PLCG1 3621/4885BTK 481/4885ITK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.